



Pharma Finance 2007

ROMA - ITALY - MAY 10-11

5TH ANNUAL PARTNERING CONFERENCE

Market Data (AS OF MAY 1, 2007)



Symbol	PYMX
Exchange	OTCBB
Current Price	\$2.10
Shares Outstanding	18.2M
Market Capital	\$38.25M
52wk RANGE	\$1.60-\$5.00
Average Volume	4,827
YTD % Change	12.31%

COMPANY FACT SHEET



PolyMedix
 170 Radner-Chester Road
 Suite 300
 Radner, PA 19087
 (484) 598-2340

www.polymedix.com



Dawn Eringis
 VP Business Development

FINANCIAL HIGHLIGHTS (YEAR ENDING DEC 31ST, 2006)

Net Revenue:	821K	Earnings per Share:	(0.72)
Net Income:	(8.86M)	Weighted Average:	12.2M

CONFERENCE OBJECTIVES

Partnering and Licensing opportunities.

RECENT DEVELOPMENTS

March 8, 2007
 PolyMedix to Present at Sachs North American Forum for Investing and Partnering in Biotech on March 12, 2007

February 13, 2007
 PolyMedix Receives Issuance of Patent for Antimicrobial Compounds

January 29, 2007
 PolyMedix Presents at 2007 Emerald Asset Management Groundhog Day Investment Forum

PRODUCT AND PRODUCT CANDIDATE PIPELINE

Oligomer/small molecule mimetics of host defense proteins

Stage: Research/Preclinical
Indication: Antibacterial, Antifungal, Antiviral
Partners Sought: Global and Regional

Polymer mimetics of host defense proteins

Stage: Research
Indication: Bactericidal materials
Partners Sought: Global and Regional

Transmembrane protein receptor crystallization of partner's protein target

Stage: Preclinical
Indication: Target dependent
Partners Sought: Global

Company Description

PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs and biomaterials for the treatment of infectious diseases and acute cardiovascular disorders. PolyMedix's compounds are based on biomimetics: non-peptide small molecule drugs that mimic the activity of proteins. The Company's antibiotic compounds - small molecule mimetics of human host-defense proteins - are believed to have a completely different mechanism of action from all current antibiotic drugs, a mechanism which is intended to make bacterial resistance unlikely to develop. These compounds are being developed as broad-spectrum, rapid-acting antibiotics for serious systemic and local infections. The Company is also developing polymeric formulations as antimicrobial biomaterials, which can be used as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces. The Company's anticoagulant antagonist compounds reverse the activity of both heparin and low molecular weight heparins, in keeping with our goal of developing an antagonist drug that is safer and easier to use than current approved therapy. PolyMedix plans to file its first IND and start human clinical trials in 2007.